Auxilium licenses Vivus's erectile dysfunction drug Stendra
This article was originally published in Scrip
Executive Summary
Now that Auxilium Pharmaceuticals has licensed Stendra (avanafil) for up to $300m plus royalties and plans to launch the erectile dysfunction drug toward the end of 2013 – more than a year and a half after the product's US FDA approval – the new management team at Vivus can cross one major item off of its to-do list.